F. Hoffmann-La Roche Ltd: Phase II/III trial shows Ronapreve (casirivimab and imdevimab) significantly reduces viral load within seven days of treatment in patients hospitalised with COVID-19
Trial met primary endpoint, showing Ronapreve significantly reduced viral load in seronegative patients hospitalised with COVID-19 who did not require high-flow oxygen or mechanical ventilation at baselineClinical
Source: finanznachrichten.de